Vestal Point Capital »

Repligen Corporation shares owned by Vestal Point Capital

Quarter-by-quarter ownership of Repligen Corporation (RGEN) shares owned by Vestal Point Capital from 13F filings

Historical chart of Vestal Point Capital investment in Repligen Corporation

Tip: Access up to 7 years of quarterly data

All positions including Repligen Corporation held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Repligen Corporation by Vestal Point Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $54M 400k 133.67

More positions owned by Vestal Point Capital

Ascendis Pharma A/S Sponsored Adr (ASND)
Arcellx Common Stock (ACLX)
Nuvalent Inc-a (NUVL)
Abivax SA Sponsored Ads (ABVX)
Alcon Ord Shs (ALC)
Bicara Therapeutics (BCAX)
Amicus Therapeutics (FOLD)
Globus Medical Cl A (GMED)
Ionis Pharmaceuticals (IONS)
Jazz Pharmaceuticals Shs Usd (JAZZ)
Becton, Dickinson and (BDX)
Scholar Rock Hldg Corp (SRRK)
Immatics NV SHS (IMTX)
Repligen Corporation (RGEN)
Dianthus Therapeutics (DNTH)

View all positions for Vestal Point Capital

Top funds holding Repligen Corporation

BlackRock
Vanguard Group
United Capital Financial Advisers
FMR
State Street Corporation
Citadel Advisors
Point72 Asset Management
Holocene Advisors
Champlain Investment Partners
Bank of New York Mellon
Alliancebernstein
Geode Capital Management
Conestoga Capital Advisors
Millennium Management
Invesco

View all funds holding Repligen Corporation